Director/PDMR Shareholding

 ("Abcam" or "the Company")

Director's and PDMRs' Dealings

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, was notified today that on 18 March 2011, the following transactions were undertaken by a Director of the Company:

Jim Warwick, an Executive Director of the Company, exercised share options over 33,000 Ordinary Shares at an exercise price of 62.4 pence per share. Following this transaction, Mr Warwick's total beneficial interest in the Company is 2,933,760 Ordinary Shares, representing approximately 1.61 per cent. of the current issued share capital of the Company. 

The Company was also notified today that on 21 March 2011, the following transactions were undertaken by PDMRs of the Company:

Jane Cooke, a PDMR of the Company, exercised share options over 44,700 Ordinary Shares at an exercise price of 62.4 pence per share. Of these, she sold 38,302 Ordinary Shares at a price of 380p per Ordinary Share. She also transferred 6,398 Ordinary Shares to her husband, David Cooke, who sold 3,199 Ordinary Shares at a price of 380p per Ordinary Share. Following these transactions, Mrs Cooke's total beneficial interest in the Company is 5,926 Ordinary Shares, representing approximately 0.003 per cent. of the current issued share capital of the Company. 

Ed Ralph, a PDMR of the Company, exercised share options over 63,995 Ordinary Shares at an exercise price of 62.4 pence per share, and subsequently sold 63,995 shares at a price of 380p per Ordinary Share. Following these transactions, Mr Ralph's total beneficial interest in the Company is 516,713 Ordinary Shares, representing approximately 0.28 per cent. of the current issued share capital of the Company. 

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 70,000 products, most of which are antibodies, from over 250 suppliers and employs 290 staff.